Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.
In 13 human immunodeficiency virus 1 (HIV-1) infected patients receiving a highly active antiretroviral therapy (HAART) annual influenza vaccination was conducted. It was hoped that HAART would prevent a post-vaccination increase in HIV-1 load and potential adverse effects. Only two patients had an increased viral load on day 14 post vaccination (p.v.). At 6 months p.v., the majority of the patients had a significantly increased CD4 cell count and a significantly decreased viral load. This indicates that HAART can protect patients from adverse consequences of influenza vaccination. The production of antibodies to the influenza A and B viruses in the HIV-infected patients was substantially lower than that in healthy persons. We propose that HIV-positive patients receiving HAART should be subjected to annual influenza vaccination.
Banic
S
S
Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana, Slovenia. srecko.koren@mf.uni-lj.si
Koren
S
S
Tomazic
J
J
Vidmar
L
L
Ihan
A
A
Poljak
M
M
Avsic-Zupanc
A
A
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007252:Influenza Vaccines / Q000009:adverse effects*; D007251:Influenza, Human / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009975:Orthomyxoviridae / Q000276:immunology; D014766:Viremia / Q000209:etiology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007252:Influenza Vaccines